Reduction of Prostate Biopsy Morbidity

This will be a prospective multi-center cohort case-control study comparing a novel transperineal prostate biopsy protocol integrating measures to reduce post procedural infection (Cases) to traditional transrectal prostate biopsies (Controls). Eligible subjects will be identified through administrative records in the Urology clinics affiliated with Maimonides Medical Center. Eligible patients will be counseled about the risks and benefits of participation and offered enrollment into the study. Demographic data including age, comorbidities and past medical history will be extracted from the medical record.

Men meeting inclusion/exclusion criteria will be prospectively enrolled. The novel transperineal protocol will include the following: (Cases)

• Transperineal biopsy approach with avoidance of rectal flora
• MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated
• Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria
• Multi-antibiotic prophylaxis
• Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.

Traditional biopsy protocol includes: (Controls)

• Transrectal approach
• Standard 12-core template
• Surgeon-specific antibiotic prophylaxis
• Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.

Inclusion criteria

• Male patients greater than 18 years of age
• Indication for prostate biopsy

Exclusion criteria

• Female patients
• Male patients under 18 years of age
• No indication for prostate biopsy